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Pfs48/45, a member of a Plasmodium-specific protein family,
displays conformation-dependent epitopes and is an important
target for malaria transmission-blocking (TB) immunity. To
design a recombinant Pfs48/45-based TB vaccine, we analyzed
the conformational TB epitopes of Pfs48/45. The Pfs48/45 pro-
tein was found to consist of a C-terminal six-cysteine module
recognized by anti-epitope I antibodies, a middle four-cysteine
module recognized by anti-epitopes IIb and III, and anN-termi-
nal module recognized by anti-epitope V antibodies. Refolding
assays identified that a fragment of 10 cysteines (10C), compris-
ing the middle four-cysteine and the C-terminal six-cysteine
modules, possesses superior refolding capacity. The refolded
and partially purified 10C conformer elicited antibodies inmice
that targeted at least two of the TB epitopes (I and III). The
induced antibodies could block the fertilization of Plasmodium
falciparum gametes in vivo in a concentration-dependent man-
ner. Our results provide important insight into the structural
organization of the Pfs48/45 protein and experimental support
for a Pfs48/45-based subunit vaccine.
Malaria parasites are spread in the human population by
Plasmodium-infected Anopheles mosquitoes. After a blood
meal on infected humans, mosquitoes become infected by
ingesting a sexual form of the malaria parasite called gameto-
cytes. Subsequent sporogonic development in the mosquito
can be prevented by the presence of anti-malaria, transmission-
blocking (TB)3 antibodies in the ingested blood meal (1–3).
Pfs48/45 is a TB vaccine candidate that belongs to a family of
malaria-specific proteins that contain conserved motifs with
four- or six-cysteine residues (4). Pfs48/45 plays a key role in
parasite fertilization (5), and monoclonal antibodies (mAbs)
against Pfs48/45 prevent fertilization (6). Anti-Pfs48/45 anti-
bodies are present in human sera fromendemic areas, and there
is evidence that the presence of anti-Pfs48/45 antibodies in nat-
ural sera correlates with TB activity (7). The induction of anti-
bodies after natural infection, as observed in the field, creates
the highly beneficial potential of vaccine boosting in the
endemic setting. At least four different epitopes (I, IIb, III, and
V) on Pfs48/45 are targeted by monoclonal antibodies that
block or reducemalaria transmission (8, 9). Apart from epitope
V, the TB epitopes are sensitive to reducing agents, which indi-
cates the importance of the disulfide bridges and hence the
conformational dependence of these epitopes (8, 10).
To design a Pfs48/45-based TB vaccine, we aimed to delin-
eate and characterize the TB epitopes of Pfs48/45. Protease
digestion of the native protein, expression in Escherichia coli of
truncations, cysteinemutations, and refolding assayswere eval-
uated by immunological analysis of the TB epitopes. An N-ter-
minally truncated protein with higher refolding efficiency was
identified, partially purified, and tested in mice immunization
experiments. The elicited antibodies recognized the native
Pfs48/45 protein, competed with the TBmAbs against epitopes
I and III, and displayed TB activity. Our study provides the first
biochemical analysis of the Pfs48/45 protein and a blueprint for
the design of Pfs48/45-based vaccines.
EXPERIMENTAL PROCEDURES
Native Pfs48/45 Protein—Mature Plasmodium falciparum
(NF54) gametocytes were produced as previously described
(11) and extracted in 25 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1.0% sodium deoxycholate, and 1 mM phenylmethylsulfonyl
fluoride. Insoluble debris was removed by centrifugation at
13,000  g for 5 min at room temperature. The supernatant
contained native Pfs48/45 protein that was used in Western
blots and enzyme-linked immunosorbent assays (ELISAs).
Antibodies—Polyclonal rabbit antiserum K96 was used to
detect recombinant Pfs48/45 (12). To detect epitopes of Pfs48/
45, various mAbs from mouse origin, 32F5 (epitope I) (6) or
from rat origin, 85RF45.1 (epitope I), 85RF45.2b (epitope IIb),
85RF45.3 (epitope III), and 85RF45.5 (epitope V) (8) were used.
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Alkaline phosphatase-conjugated antisera were purchased
from Sigma and horseradish peroxidase (HRP)-conjugated
antisera from Nordic.
Partial Protease Digestion and Purification of Pfs48/45 Pro-
tease Fragment—Partial protease treatment was conducted
with trypsin (sequencing grade, Roche Applied Science). For
each digestion, 5  105 gametocyte equivalents of the above-
described deoxycholate extract were used. The proteins were
digested at 25 °C for 1 h. The amount of protease varied from
0.01, 0.1 to 1 g in a final reaction volume of 10 l. The
digestion was stopped by adding a protease inhibitor mixture
(CompleteTM, Roche Applied Science). For preparative immu-
nopurification of protease fragments, 1  108 gametocyte
equivalents were digested with 1 g/ml trypsin for 2.5 h at
30 °C. A 28-kDa fragment was purified usingmAb 32F5 against
Pfs48/45 epitope I. This mAb 32F5 was cross-linked to protein
G-Sepharose 4B Fast Flow (Sigma) using dimethylpimelimidate
(Sigma) (13). The trypsin-treated extract was incubated over-
night at 4 °C with the cross-linked beads and washed three
times with 0.1% deoxycholate in phosphate-buffered saline
(PBS) and three times with RIPA buffer as described in Ref. 13.
Bound proteins were eluted twice with 500 l of 1% SDS in PBS
at 70 °C (14). To identify the 28-kDa fragment, the eluted pro-
teins were SDS-PAGE-separated and stained with Coomassie
Blue R-250 (Sigma). The 28-kDa doublet was sliced out from
the gel and analyzed by liquid chromatography/tandem mass
spectrometry (LC-MS/MS), as previously described (15).
Constructs of Truncated andMutated Pfs48/45—The coding
sequence of Pfs48/45 (14) without the predicted signal peptide
and glycosylphosphatidylinositol signal sequence (amino acids
27–427) was cloned into pGEX-2T (Amersham Biosciences),
resulting in an N-terminal glutathione S-transferase (GST)
fusion. N-terminally truncated Pfs48/45GST fusions were gen-
erated using standard cloning techniques. Cysteines were
mutated to serines by site-directed mutagenesis (QuikChange,
Stratagene). For refolding experiments, Pfs48/45 fragments
were cloned in the vector pET-15b (Novagen), resulting in
N-terminally His6-tagged proteins. All constructs were verified
by sequencing using BigDye (Applied Biosystems, ABI) and the
ABI PRISM 310 genetic analyzer.
Purification and Refolding of E. coli-expressed Proteins—The
tagged proteins (GSTorHis) were expressed in theE. coli strain
BL21 DE3 (Novagen) by induction for 3 h at 37 °C with 0.1 mM
isopropyl 1-thio--D-galactopyranoside (GST fusions) or 1 mM
isopropyl 1-thio--D-galactopyranoside (His-tagged) at an
A600nm of 0.6. The expressed proteins were analyzed in crude
lysates or after affinity purification. Bacteriawere lysed by ultra-
sonic homogenization in PBS, 1 mg/ml lysozyme, 0.1% Triton
X-100, 1 mM phenylmethylsulfonyl fluoride, and 1 protease
inhibitor mixture (CompleteTM, Roche Applied Science). After
centrifugation (10,000  g for 15 min at 4 °C), pellets contain-
ing the inclusion bodies werewashedwith 0.5%TritonX-100 in
10 mM Tris, pH 8.0, and 1 mM EDTA followed by 0.5% Triton
X-100 in 10 mM Tris, pH 8.0. The His-tagged proteins were
purified using Ni-NTA beads (Qiagen) after solubilization of
the inclusion bodies in 8 M urea, 50 mM Tris-HCl, pH 8, 0.5 M
NaCl, and 1 mM -mercaptoethanol. Following centrifugation
(10 min 10,000  g), the supernatant was loaded on a 10-ml
disposable column (Bio-Rad) with a 400-l bed volume of NTA
beads. After 30 min of incubation at room temperature during
slow vertical rotation, the beads were allowed to settle and the
column was washed with 10 bed volumes of solubilization
buffer and 10 bed volumes of 8 M urea, 50 mM Tris-HCl, pH 8,
and 1mM reduced glutathione. The tagged proteinswere eluted
two times with 0.75ml of 10mM EDTA in 8 M urea, 0.5 MNaCl,
50 mM Tris-HCl, pH 8.0, and 1 mM glutathione. The eluted
proteins at a concentration of 0.25 g/l were 8-fold drop-
wise-diluted in renaturation buffer (PBS, 0.1% Triton X-100,
1 mM reduced glutathione, and 1 protease inhibitor mix-
ture (CompleteTM, Roche Applied Science) and refolded
overnight at 4 °C.
Refolding on Column and Purification of 10C Fragment—In-
clusion bodies were prepared and solubilized as described
above. The protein was then bound to a Ni-NTA resin, and the
columnwas washed with 8 M urea, 50mMTris-HCl, pH 8, 0.5 M
NaCl. The protein was refolded by subsequent buffer exchange
to PBS that contained 0.1% Triton X-100, and the bound,
refolded protein was eluted with 10 mM EDTA in the above-
described buffer. The eluted proteins were 50-fold-concen-
trated on Vivaspin 20, 30,000 molecular weight cutoff filters
(Vivascience). Insoluble aggregates were removed by centrifu-
gation (30 min at 13,000  g), and protein was further purified
over a Superdex 75HR 10/30 column (AmershamBiosciences).
SDS-PAGE and Immunoblot Analysis—Protein samples
were mixed with an equal amount of SDS-PAGE loading buffer
(4% SDS, 100 mM Tris-HCl, pH 6.8, 20% glycerol, and 0.02%
bromphenol blue) and, unless otherwise indicated, boiled for 5
min at 95 °C without any reducing agent. The samples were
resolved on 10% SDS-PAGE gels and visualized by Coomassie
Blue R-250 staining. The presence of Pfs48/45 and epitope rec-
ognition was analyzed by immunoblot analysis using nitrocel-
lulose filters (Protran, Schleicher & Schuell). The electro-
phoretic transfer was carried out for 2 h at 50 V, 100 mA. The
membranes were blocked overnight at 4 °C in 4% milk (Elk,
Campina, The Netherlands) in PBS with 0.2% Tween 20
(PBST). Incubations with primary (1.5 h) and secondary mAbs
(1 h) were performed in blocking buffer. The filters were
washed three times for 5 min with PBST in between antibody
incubations. ECL substrate (Amersham Biosciences) and nitro
blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate sub-
strate (13) were used for detection.
Animal Immunizations—Groups of female BALB/c mice (6
weeks old, five mice/group) were immunized subcutaneously
with recombinant 10C fragment or parasites in a total volume
of 0.1 ml emulsified in complete Freund’s adjuvant, and boosts
were given after 28, 42, and 133 days using incomplete Freund’s
adjuvant. Group 1 was immunized with 25 g of recombinant
10C per mouse, group 2 with 106 NF54 parasites, group 3 with
105 NF54 parasites, and group 4 was immunized with adjuvant
alone. Serum was collected on days 0, 14, 42, 56, and 147 and
tested for specific antibody reactivity.
Immunofluorescence Assay (IFA)—An indirect IFA was per-
formedwith amix of cultured asexual and sexual stage parasites
(NF54 isolate of P. falciparum) air-dried on multispot slide, as
described previously (8, 11). Briefly, parasites were incubated
with a 1:100 dilution of the test sera in PBS, rinsedwithPBS, and
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incubated with fluorescein isothiocyanate-conjugated goat
anti-mouse IgG (MP Biomedicals). The slides were rinsed,
washed,mounted under a coverslip, and examined under ultra-
violet illumination with a Leitz Ortholux fluorescence micro-
scope (500 magnification). For surface IFA (SIFA) analysis,
gametocytes were allowed to undergo gametogenesis, as
described previously (8, 11). Subsequently, suspension of mac-
rogametes/zygotes (100 l) was mixed with 100 l of a 1:100
dilution of the sera in PBS and incubated for 20 min on ice.
Parasites were washed with 1 ml of PBS, collected by centrifu-
gation for 3min at 3000 revolutions/min (benchtop centrifuge),
and incubated with 50 l of fluorescein isothiocyanate-conju-
gated goat anti-mouse IgG (MPBiomedicals). After awashwith
PBS, the cells were examined as described for the IFA.
Direct ELISA—ELISA plates were coated overnight with
gametocyte extract (250,000 parasites/well) in PBS. After
blocking with 5% milk in PBS, sera (in the desired dilutions)
were incubated for 2 h. Bound antibodies were detected by
HRP-conjugated goat anti-Mouse IgG and visualized using
3,3,5,5-tetramethyl benzidine substrate, as previously
described (8, 11).
Pfs48/45-specific ELISA—A two-sided ELISAwas performed
as previously described (8, 11). Samples were treated with 10
mM iodoacetamide just before the serial dilution to prevent
refolding in the wells. The amount of the native Pfs48/45 pro-
tein in the gametocyte extract was predetermined by Western
blot analysis under reducing conditions, using the polyclonal
antiserumK96 (12) and the recombinant protein as a reference.
Competition ELISA—The Pfs48/45 protein present in game-
tocyte extract was captured essentially as for the Pfs48/45-specific
ELISA using mAb 85RF45.2b. Competition of HRP-labeled
85RF45.1 or 85RF.45.3 with sera antibodies from 10C-immu-
nized mice was performed by incubation of 30 l of HRP-la-
beled mAb (2.5 g/ml, diluted with PBS containing 0.1% milk)
and 30 l of mice serum (dilutions ranging from 1:20 to 1:2560
diluted with PBS containing 0.1% milk) for 2 h. Bound, labeled
mAbs were measured as described above.
StandardMembrane-feedingAssay—Antisera obtained from
mice immunized with the 10C fragment were compared for
their TB activities in standard membrane-feeding assays, as
previously described (16, 17). Briefly, 30l of themice serawere
mixed with 60 l of naı̈ve human serum and 180 l of in vitro
gametocyte culture of P. falciparum (NF54 line). This mixture
was fed to Anopheles stephensi mosquitoes (Nijmegen strain)
through a membrane-feeding apparatus. Sera from mice
immunizedwith PBS buffer alone served as the controls. Blood-
fedmosquitoes were kept at 26 °C and 80% humidity for 7 days.
Surviving mosquitoes (90%) were dissected and oocysts
counted from extracted midguts. Twenty mosquitoes/batch
were examined for the presence of oocysts. A standard mem-
brane-feeding assay experiment was considered valid when, in
three control batches of mosquitoes fed on naı̈ve human serum
and in vitro gametocyte culture, the percentage of infected
mosquitoes was 90% or more.
RESULTS
Protease Mapping of the Pfs48/45—To elucidate the domain
organization of the Pfs48/45 protein, trypsin digestion was used.
Trypsin recognition sites that are buried inside the protein should
be relatively inaccessible. The Pfs48/45 protein contains, in
total, 51 Lys and Arg residues, all of which are potential trypsin
cleavage sites. Fig. 1 shows the result of a trypsin digestion on
gametocyte extract separated under non-reducing conditions
on SDS-PAGE and analyzed by immunoblot with anti-Pfs48/45
epitope I mAb. A doublet migrating at 28 kDa reacted with
TB epitope I (Fig. 1A) as well as with IIb and III mAbs but not
with epitope V mAb (data not shown). Immunopurification of
the 28-kDa doublet using epitope I mAb and subsequent LC-
MS/MS analysis identified peptides between residues 164 and
404 with a corresponding molecular weight of 28 kDa. Thus,
Pfs48/45 contains a C-terminal part of the 28-kDa that is rela-
tively resistant to trypsin cleavage and that displays conforma-
tional epitopes I, IIb, and III. At higher trypsin concentrations,
a minor 18-kDa fragment was generated with weak epitope I
(Fig. 1B) but with no epitopes IIb and III reactivity (data not
shown).
Expression of GST-fused N-terminal Pfs48/45 Truncations in
E. coli—To determinemore precisely which regions are critical
for epitope formation, full-length Pfs48/45without itsN-termi-
nal signal peptide sequence and its C-terminal signal for attach-
ment of a glycosylphosphatidylinositol moiety (amino acids
27–427), the 16C fragment (Fig. 2A), and truncations thereof
were constructed and expressed as N-terminal GST fusions in
E. coli. Total E. coli proteins were boiled in SDS sample buffer
with 50 mM dithiothreitol, resolved by SDS-PAGE, and blotted
onto nitrocellulose membranes. The observed reactivity with
the mAbs after blotting is likely a result of refolding of the pro-
FIGURE 1. Trypsin digestion of the native Pfs48/45. A, gametocyte extract
(5  105 gametocyte equivalents) was treated with increasing amounts of
trypsin for 1 h at 25 °C. Lanes 1– 4, 0.01, 0.1 to 1 g of trypsin. The samples were
resolved by non-reducing SDS-PAGE and immunoprobed with anti-epitope I
mAb. B, Pfs48/45 amino acid sequence. LC-MS/MS-identified peptides of the
28-kDa fragment are underlined.
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tein on the nitrocellulose membrane. Expression of full-length
Pfs48/45 fused to GST (Fig. 2B, 16C) resulted in a protein of
80kDathatwasrecognizedbythepolyclonal,non-conformation-
dependent K96 sera (12) and by the mAbs recognizing epitopes
I, IIb, III, and V (8) (Fig. 2B). A second polypeptide with an
apparent molecular weight of 30 kDa was detected, which was
generated by the initiation of translation at an internal start
codon atmethionine 174 due to the presence of a Shine-Delgano-
likemotif. This polypeptidewas recognized bymAbs I, IIb, and III
and was absent when using constructs shorter than 10C; it
migrated at the same position as 10C without the GSTmoiety.
In line with the trypsin sensitivity assays, the 10C fragment
could be detected by epitopes I, IIb, and IIImAbs. Furthermore,
epitopes IIb and III were present in
the 10C but not in the 8C or shorter
fragments. Epitope I was present in
all of the C-terminal truncations,
including the 6C fragment (Fig.
2B). The mAb against epitope V
displayed a much stronger reactiv-
ity with the 16C than the 12C con-
struct, and no reactivity could be
detected against the 10C or shorter
fragments. Thus, the region be-
tween cysteines 4 and 7 appeared to
be essential for epitope V, and the
region N-terminal to cysteine 4
appeared to contribute to epitope V
formation.
Epitope Mapping by Cysteine
Mutations—To investigate which
cysteines are important for theproper
formation of the TB epitopes, each
cysteine was mutated to serine in
the full-length Pfs48/45 fused to
GST (16C). These sixteen individual
mutants were expressed in E. coli
and screened for the formation of
conformational epitopes I, IIb, III,
and V.
In line with the previously pro-
posed structural organization of
Pfs48/45 (4, 18), mutations of any of
the six cysteines in the putative C-terminal domain led to the
specific loss of epitope I recognition (Fig. 3). This finding cor-
roborated and extended our N-terminal truncation analysis
and led to the conclusion that the epitope I mAb recognizes a
conformational epitope at the C terminus of Pfs48/45 that
requires proper pairing of six cysteines.
Mutations of any of the four cysteines in the putative middle
domain affected the recognition of epitopes IIb and III but did
not affect I and V. Hence, the middle four-cysteine part of the
protein appears to form an independent conformational unit,
in agreement with the N-terminal deletion experiments and
previously proposed structural organization of Pfs48/45 (4, 18).
None of the cysteine mutations affected epitope V (Fig. 3), in
line with the fact that this epitope is not sensitive to reducing
agents (10).
Refolding and Purification of the Recombinant Proteins—In
E. coli, the Pfs48/45 protein as well as truncations fused to GST
ended up in inclusion bodies. To allowpurifications from inclu-
sion bodies, we constructed N-terminal His6-tagged 16C, 12C,
10C, and 6C proteins. Reduction of the purified proteins before
loading on gel and subsequent refolding on the nitrocellulose
membrane showed that the 10C, 12C, and 16C (but not 6C)
fragments could be partially refolded with respect to epitope I
(Fig. 4, A and B). The proteins were further analyzed for their
refolding potential by dilution in renaturation buffer. Two-
sided capture ELISA experimentation using mAb III for cap-
ture andmAb I and IIb for detectionwas employed to detect TB
epitopes generated upon refolding (Fig. 4C). Gametocyte
FIGURE 2. Effects of N-terminal truncations on the Pfs48/45 TB epitopes. A, a schematic representation of
the Pfs48/45 protein. The coding sequence contains a total of 448 amino acids and includes an N-terminal
signal peptide (SP) and a C-terminal signal for attachment of a glycosylphosphatidylinositol (GPI) moiety. Bars
indicate the relative position of cysteine residues. Methionine (M) at position 174 is indicated on top as a most
likely internal translation initiation product. B, overview of N-terminal truncations. Shown are 16C (residues
27– 427), 12C (108 – 427), 10C (173– 427), 8C (236 – 427), and 6C (295– 427), which are expressed in E. coli as
fusions with GST. Crude E. coli extracts were screened with mAbs against epitopes I, IIb, III, and V and anti-
Pfs48/45 polyclonal sera K96. Samples were boiled in SDS sample buffer with 50 mM dithiothreitol prior to
loading on SDS-polyacrylamide gels. The observed reactivity is an expected result of refolding on the blot.
Asterisks indicate the position of the internal translation initiation product.
FIGURE 3. Effects of cysteine mutations on the Pfs48/45 TB epitopes. Indi-
vidual cysteine to serine substitutions (Cys-1–Cys-16) were introduced in the
GST-16C construct (see Fig. 2B). Upon expression in E. coli and refolding on
the nitrocellulose membrane, the recognition of by mAbs was analyzed by
Western blots.
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extracts with empirically determined concentrations of native
Pfs48/45 protein were used as standards. Of the tested recom-
binant products, the 10C displayed the highest refolding poten-
tial with respect to the formation of TB epitopes.
Next, we performed a series of refolding experiments to opti-
mize our refolding conditions. Different conditions such as
redox couples, temperature, incubation time, urea concentra-
tion, type and amount of detergents, and refolding by dilution
and on various types of columns with one-step, gradient, or
cyclic renaturation were tested. Single step refolding on a Ni-
NTA column yielded the highest refolding efficiency (data not
shown). The refolding yielded aggregates in addition to a num-
ber of distinct monomeric conformers (Fig. 5A). Subsequent
concentration by diafiltration and purification on a Superdex
75 column separated monomeric
conformers from the aggregates
(Fig. 5B). Although several mono-
meric conformers were observed
under non-reduced SDS-PAGE
(Fig. 5B), only one band with an
apparent molecular weight of 28
kDa reacted with the mAbs. Cap-
ture ELISA experiments (Fig. 5C)
extended the Western blot results,
showing that a fraction of the
refolded 10C material displayed
proper TB epitopes. Approximately
10–20% of the proteinwas correctly
folded, i.e. displayed TB epitopes as
estimated from the ELISAs, West-
ern blots, and the silver-stained
SDS-PAGE.
Immunogenicity of the Recombi-
nant 10C Preparation—The immu-
nogenicity of the refolded and
partially purified 10C protein
preparation was assessed by
immunization of BALB/c mice.
Groups of mice immunized with
105 or 106 P. falciparum (NF54)
gametocytes or buffer (PBS) and
adjuvant alone served as controls.
Mice immunized with the 10C
(but not the controls) induced
antibodies that detected two
bands in gametocyte extracts with
the expected mobility of 48 and 45
kDa on Western blots (data not
shown). The immune responses
were furthermore assessed by
gametocyte ELISAs against total
gametocyte antigens (Fig. 6A) and
Pfs48/45 ELISA in which native
Pfs48/45 was captured by a mAb
(Fig. 6B). When analyzed in the
gametocyte ELISA, the 10C frag-
ment induced titers of 1/11,400
(S.D.  1/8,355), which was ap-
proximately four times lower as compared with mice immu-
nized with 106 gametocytes 1/40,000 (S.D.  1/14,142) and
in a range similar to that of mice immunized with 105 game-
tocytes 1/7,500 (S.D.  1/2,179) (Fig. 6A). Pfs48/45 ELISA
revealed antibodies specific for the Pfs48/45 protein with a
mean optical density for the five mice of 0.958 (S.D.  0.447)
(Fig. 6B).
The ability of the antiserum to recognize native gametocyte
or macrogamete protein was further assessed by IFA against
whole dried sexual stage parasites and surface immunofluores-
cence assay (SIFA) using live intact macrogametes/zygotes.
Four of five mice sera (10C1, 10C2, 10C4, and 10C5) showed
good reactivity to the gametocytes and macrogametes/zygotes
but not against asexual stages or Pfs48/45 knock-out parasites.
FIGURE 4. Refolding efficiency of the His-tagged N-terminal truncations. His-tagged C-terminal
Pfs48/45 fragments 6C, 10C, 12C, and 16C were expressed in E. coli and purified by Ni-NTA beads. After
boiling in sample buffer with 50 mM dithiothreitol, proteins were separated on a SDS-polyacrylamide gel
and stained using Coomassie Blue R-250 (A) or immunoblot using anti-epitope I (B). C and D, shown are
His-tagged 6C, 10C, 12C, and 16C constructs analyzed by two-sided ELISAs using rat mAbs against epitope
III for capture and HRP-labeled rat mAbs for detection. On the y-axis, the optical density at 450 nm is shown
(OD 450 nm). The gametocyte extract with known concentrations of the Pfs48/45 protein was used as a
positive control. The refolded proteins were treated with 10 mM iodoacetamide before dilution to prevent
refolding in the microtiter plate.
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The reactivity of the 10C1 serum is shown in Fig. 6C. Sera from
mice immunized with buffer and adjuvant did not show a
detectable signal (not shown).
Having established the presence of antibodies specific against
the native Pfs48/45 in the 10C-immunized mice, we investigated
whether the antibodies target knownTB epitopes (I and III). Fig. 7
shows a competitionof themice sera against a constant amount of
peroxidase-conjugated rat anti-epitope I and III mAbs. The same
(but not conjugated) rat anti-epitopes I and IIImAbswere used as
positive controls and for quantification. All five sera from the 10C
immunization competed with the conjugated epitope I mAb,
whereas the control sera of adjuvant-immunized mice as well as
the preimmune (S0) sera did not (Fig. 7A).
Estimations from the amount of competitions in the mice
sera compared with the competition observed with the non-
conjugated rat mAb revealed that 10C1 serum contained anti-
epitope I antibodies at concentrations of 20 g/ml. Sera
10C2, 10C3, and 10C5 contained lower titers of anti-epitope I
antibodies of 6 g/ml. The lowest epitope I competitor 10C4
contained anti-epitope I antibodies in the range of 1–2 g/ml.
Competition with a non-TB epitope III mAb was observed for
two of the 10C-immunized mice (Fig. 7B). For the 10C1 serum,
anti-epitope III antibodies were estimated to be 100 g/ml
and for the 10C4 20 g/ml.
Previous characterizations of the anti-epitope I mAb
revealed that a concentration of 12 g/ml or more completely
blocks transmission (8). Hence, the concentrations of the anti-
epitope I antibodies in the 10C1 serum was in the range
expected to yield TB effects. The sera 10C2, 10C3, and 10C5
were expected to yield transmission-reducing effects.
Transmission-blocking Activity Induced by the 10C Fragment—
Antisera obtained frommice immunized with the recombinant
FIGURE 5. Recognition by TB mAbs of the refolded 10C fragment. A, reduced
(left panel) and non-reduced (right panel) silver-stained SDS-PAGE of the Pfs48/45
10C fragment after refolding on a Ni-NTA column. The arrow indicates the posi-
tion of the conformer with correct conformation. B, non-reduced silver stain and
Western blot analysis of the 10C fragment after the Superdex 75 purification step
analyzed with anti-epitopes I, IIb, and III mAbs. C, two-sided ELISA experiment
with rat mAbs against epitope IIb (upper panel) or III (lower panel) for capture of
the antigen- and peroxidase-labeled mAb against epitope I for detection. Each
dilution point is repeated twice in parallel. The amount of the Pfs48/45 present in
the gametocytes was previously determined by titration on a reduced Western
blot using polyclonal sera K96 and recombinant Pfs48/45 produced in E. coli as a
reference.
FIGURE 6. Immunogenicity of the 10C fragment. A, gametocyte ELISA anti-
body reactivity to total gametocyte extract of sera from mice immunized with
recombinant 10C or gametocytes (GCT). Data are presented as a mean
titer  S.D. of the five mice sera. B, antibody reactivity to Pfs48/45 captured by
rat mAb 85RF45.3 in sera from mice immunized with the 10C or gametocytes.
Data are presented as mean optical density  S.D. of the five mice at a dilu-
tion of 1/200 of the serum. Shown are immunofluorescence microscopy on
P. falciparum gametocytes air-dried on a multispot slide (IFA) (C) and on live
intact macrogametes/zygotes (SIFA) with anti-10C mouse sera (D).
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10C fragment were analyzed for their TB activities relative to
the anti-epitope I competition ELISA. As shown in Fig. 8, the
strongest anti-epitope I competitor (10C1) blocked almost
completely the oocyst development inside the mosquito mid-
gut by reducing the mean oocyst number from 7 in the con-
trols to 0.45. Sera with intermediate anti-epitope I antibodies
(10C2, 10C3, and 10C5) reduced the oocyst numbers by 50%.
As expected, the concentration of anti-epitope I antibodies cor-
related to the TB reactivity. Although achieving consistent and
high titers of TB antibodies will be required for future vaccine
development, the data presented here show that TB antibodies
against the native Pfs48/45 can be
induced in mice using a recombi-
nant, refolded Pfs48/45 protein
fragment.
DISCUSSION
Our study provides the first bio-
chemical and immunological char-
acterization of Pfs48/45 and dem-
onstrates that an N-terminally
truncated Pfs48/45 protein, coined
10C, possesses the highest refolding
capacity andelicitsTBantibodies that
canblock the fertilizationof theP. fal-
ciparum gametes in a concentration-
dependent manner.
A multimodule organization of
the Pf48/45 protein emerged as a
result of extensive analysis using
conformationally dependent anti-
bodies against Pfs48/45. A C-termi-
nal module containing a six-cys-
teine module was recognized by
mAb against epitope I, a middle
module containing a four-cysteine
module was recognized by mAbs
against epitopes IIb and III, and an
N-terminal module also containing
a six-cysteine motif was recognized
by the epitope V mAb. The cys-
teines in the central and the C-ter-
minal modules appear to be crucial
for proper presentation of the TB
epitopes I, IIb, and III. Proper dis-
play of the TB-blocking epitope V in
the N-terminal module did not
depend on cysteines nor was it sen-
sitive to treatment with reducing
agents (10). Limited trypsin diges-
tion and refolding experiments
indicated that the middle four-
cysteine and the C-terminal six-cys-
teinemodule are likely to interact to
form one stable domain of 10 cys-
teines, whereas the N-terminal
module of Pfs48/45 appears to form
a separate domain.
Similarly, related four- and six-cysteine modules are present
in ten other unique-to-Plasmodium proteins (4, 18). Taken
together, our study corroborates and extends previous in silico
predictions on the disulfide bond structures and domain orga-
nization of Pfs48/45 and related proteins (4, 18). Althoughmost
of the Pfs48/45-related family members are largely uncharac-
terized, some of them are obvious TB vaccine candidates.
Pfs48/45, P36p (5, 19), and Pfs230 (20) are expressed on the
surface of the parasite and have an essential function in devel-
opment. In addition, Pfs230 and Pfs48/45 are direct targets for
TB antibodies (11, 20, 21). Although recombinant expression of
FIGURE 7. Two-sided competition ELISAs. mAb against epitope II (85F45.2b) was used to capture a Pfs48/45
molecule from the gametocyte extract. The competition of mice sera immunized with the 10C protein (10C1 S4,
10C2 S4, 10C3 S4, 10C4 S4, 10C5 S4), buffer (PBS S4), or preimmune 10C1 S0 was titrated against a constant
amount of peroxidase-labeled mAb anti-epitope I (85RF45.1) (A) or anti-epitope III (85RF45.3) (B). Serum dilu-
tions (from 1/20 –1/2560 (5% to 0.039% v/v)) are indicated. Unlabeled 85RF45.1 (A) or 85RF45.3 (B) was used as
indicated on the secondary x-axis concentrations as standard references.
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these proteins in a proper conformation is expected to be cum-
bersome, combinations of various four- and six-cysteine mod-
ules may yield a successful production strategy. Cloning and
expression of protein fragments similar to 10C (four-cysteine
module adjacent to six-cysteine module) from Pfs230 or other
related proteins is expected to reveal the feasibility of this
approach.
Previous studies have revealed that, in particular, epitope I
has strong TB potential (8). This property seems not related to
the origin of mAb itself but specific for the epitope that it rec-
ognizes, as all of the types ofmAbs against epitope I (mouse and
rat) block transmission completely, whereas mAbs against
epitopes IIb and III have no effect on their own (8). The C-ter-
minal six-cysteinemodule turned out to be theminimal portion
of Pfs48/45 that could display epitope I (Fig. 4). It appeared,
however, that the fragment was not stable upon storage and
highly sensitive to reducing conditions (data not shown). Inter-
estingly, we consistently observed that the C-terminal six-cys-
teine module readily displayed epitope I on immunoblot when
expressed as aGST fusion (Fig. 2) but notwith the hexahistidine
tag (Fig. 4). Apparently, the GST moiety has a stabilizing effect
on the conformation of Pfs48/45, similar to the middle four-
cysteine module itself. The 10C fragment was stable upon stor-
age and more resistant to treatment with reducing agents than
the C-terminal 6C fragment (data not shown). Superdex 75-en-
riched 10C conformer can be stored for at least 8 weeks at 4 °C
without detectable loss of reactivity with TB mAbs.
The ability of the refolded and partially purified 10C frag-
ment to induce TB antibodies in rodent models such as mice
was subsequently demonstrated in immunization experiments.
The protein is immunogenic, as it induced antibodies that spe-
cifically recognized the native Pfs48/45 protein. Competition
ELISAs revealed that Pfs48/45 antibodies directed against TB
blocking epitope I are present in the sera of mice immunized
with the 10C protein. The concentration of epitopes I and III
antibodies varied in the fivemice; one 10C1 was in the required
range to efficiently block transmission (20 g/ml). The same
sera contained anti-epitope III antibodies at a concentration of
100g/ml, indicating that epitope III is immunodominant over
epitope I, which is in accordance with the observation that sera
from malaria-exposed individuals contain predominantly
non-TB anti-epitope III antibodies and relatively low levels of
anti-epitope I antibodies (11). Apparently, themiddle four-cys-
teine module, recognized by epitope III, retains higher immu-
nogenicity as compared with the six-cysteine module, recog-
nized by epitope I. The six-cysteine module from the other
hand is crucial for the protective efficacy.
The potency of malaria TB vaccines is, among others,
dependent on the concentration of the induced antibodies and
the quantity of the fertilization-competent gametocytes (8, 22,
23). Thus, the required magnitude of antibody responses is
expected to depend on the load of mature gametocytes. Field
data indicate that low concentrations of “submicroscopic”
(5000 gametocytes/ml) gametocytemia constitute a consider-
able proportion (75%) of the human infectious reservoir in e.g.
Kenyan children (24). Mosquito infection rates for these sub-
microscopic carriers are 4.1%; for the other carriers with
microscopic densities, the infections rates are 8.3%. In our
transmission blocking assays, mosquitoes were fed on in vitro
grown gametocyte cultures that contained 1.5  106/ml
mature gametocytes with infection rates of 90% of the fed
mosquitoes. Therefore, it is expected that, under field condi-
tions, the 10C-induced antibody responses may yield sufficient
TB effects.
The variability in the amount of induced antibody titers in
the five 10C-immunizedmice resulted in variability in outcome
on the TB assay. For the future, it will be necessary to achieve
uniform, sustained, and high titer anti-epitope I antibody
responses in all of the 10C-immunized animals or human indi-
viduals. For Pfs25H, another malaria TB vaccine candidate, the
chemical conjugation to the outer membrane protein complex
of the Neisseria meningitidis serogroup B and adsorption to
aluminumhydroxyphosphate induced high and persistent anti-
body levels that yielded the desired uniform TB activity (25).
This or similar approaches, as described in Ref. 26 or 27, will be
useful in the future in Pfs48/45-based vaccine formulations, as
they are expected to yield higher andmore uniform titers of TB
antibodies and guarantee the efficacy of the 10C vaccine.
In conclusion, the induction of TB antibodies using recom-
binant Pfs48/45 subunit protein provided a proof-of-concept
for a recombinant Pfs48/45-based TB vaccine. Future efforts
will be directed toward achieving a more homogeneous and
correctly folded 10C preparation as well as improving the
immunization schemes and vaccine formulations.
Acknowledgments—We thankGeert-Jan vanGemert for culturing the
parasites and Wynand Eling for helpful discussions.
REFERENCES
1. Carter, R., Mendis, K. N., Miller, L. H., Molineaux, L., and Saul, A. (2000)
Nat. Med. 6, 241–244
2. Carter, R. (2001) Vaccine 19, 2309–2314
3. Kaslow, D. C. (2002) Chem. Immunol. 80, 287–307
4. Gerloff, D. L., Creasey, A., Maslau, S., and Carter, R. (2005) Proc. Natl.
FIGURE 8. Transmission blocking activity correlates to the concentration
of the anti-epitope I antibodies. Mean oocyst numbers/mosquito (n  20)
are related to the concentration of the anti-epitope I antibodies in the sera
from mice immunized with the 10C protein (10C1 S4, 10C2 S4, 10C3 S4, 10C4
S4, 10C5 S4), or PBS buffer (PBS S4) as measured by competition ELISA and
displayed as a percentage of competition against epitope I mAb.
Pfs48/45 Domain Organization and Subunit Vaccine Design
JUNE 8, 2007 • VOLUME 282 • NUMBER 23 JOURNAL OF BIOLOGICAL CHEMISTRY 17155
Acad. Sci. U. S. A. 102, 13598–13603
5. van Dijk, M. R., Janse, C. J., Thompson, J., Waters, A. P., Braks, J. A.,
Dodemont, H. J., Stunnenberg, H. G., van Gemert, G. J., Sauerwein, R.W.,
and Eling, W. (2001) Cell 104, 153–164
6. Vermeulen, A. N., Roeffen,W. F., Henderik, J. B., Ponnudurai, T., Beckers,
P. J., and Meuwissen, J. H. (1985) Dev. Biol. Stand. 62, 91–97
7. Roeffen,W., Lensen, T.,Mulder, B., Teelen, K., Sauerwein, R., VanDruten,
J., Eling, W., Meuwissen, J. H., and Beckers, P. J. (1995) Am. J. Trop. Med.
Hyg. 52, 60–65
8. Roeffen,W., Teelen, K., vanAs, J., Vegte-Bolmer,M., Eling,W., and Sauer-
wein, R. (2001) Exp. Parasitol. 97, 45–49
9. Carter, R., Graves, P. M., Keister, D. B., and Quakyi, I. A. (1990) Parasite
Immunol. (Oxf.) 12, 587–603
10. Targett, G. A., Harte, P. G., Eida, S., Rogers, N. C., and Ong, C. S. (1990)
Immunol. Lett. 25, 77–81
11. Roeffen, W. F., Raats, J. M., Teelen, K., Hoet, R. M., Eling, W. M., van
Venrooij, W. J., and Sauerwein, R. W. (2001) J. Biol. Chem. 276,
19807–19811
12. Milek, R. L., Roeffen, W. F., Kocken, C. H., Jansen, J., Kaan, A. M., Eling,
W. M., Sauerwein, R. W., and Konings, R. N. (1998) Parasite Immunol.
(Oxf.) 20, 377–385
13. Harlow, E., and Lane, D. (1988) Antibodies, A Laboratory Manual, Cold
Spring Harbor Laboratory, New York
14. Kocken, C. H., Jansen, J., Kaan, A. M., Beckers, P. J., Ponnudurai, T.,
Kaslow, D. C., Konings, R. N., and Schoenmakers, J. G. (1993) Mol. Bio-
chem. Parasitol. 61, 59–68
15. Lasonder, E., Ishihama, Y., Andersen, J. S., Vermunt, A. M. W., Pain, A.,
Sauerwein, R. W., Eling, W. M. C., Hall, N., Waters, A. P., Stunnenberg,
H. G., and Mann, M. (2002) Nature 419, 537–542
16. Ponnudurai, T., Lensen, A. H., Van Gemert, G. J., Bensink, M. P., Bolmer,
M., and Meuwissen, J. H. (1989) Parasitology 98, 165–173
17. Lensen, A., van Druten, J., Bolmer, M., van Gemert, G., Eling, W., and
Sauerwein, R. (1996) Trans. R. Soc. Trop. Med. Hyg. 90, 20–22
18. Carter, R., Coulson, A., Bhatti, S., Taylor, B. J., and Elliott, J. F. (1995)Mol.
Biochem. Parasitol. 71, 203–210
19. van Dijk, M. R., Douradinha, B., Franke-Fayard, B., Heussler, V., van
Dooren,M.W., van Schaijk, B., vanGemert, G. J., Sauerwein, R.W.,Mota,
M. M., Waters, A. P., and Janse, C. J. (2005) Proc. Natl. Acad. Sci. U. S. A.
102, 12194–12199
20. Williamson, K. C. (2003) Parasite Immunol. (Oxf.) 25, 351–359
21. Roeffen, W., Mulder, B., Teelen, K., Bolmer, M., Eling, W., Targett, G. A.,
Beckers, P. J., and Sauerwein, R. (1996) Parasite Immunol. (Oxf.) 18,
103–109
22. Vermeulen, A. N., Ponnudurai, T., Beckers, P. J., Verhave, J. P., Smits,
M. A., and Meuwissen, J. H. (1985) J. Exp. Med. 162, 1460–1476
23. Ponnudurai, T., van Gemert, G. J., Bensink, T., Lensen, A. H., and Meu-
wissen, J. H. (1987) Trans. R. Soc. Trop. Med. Hyg. 81, 491–493
24. Schneider, P., Bousema, J. T., Gouagna, L. C., Otieno, S., van de Vegte-
Bolmer, M., Omar, S. A., and Sauerwein, R. W. (2007) Am. J. Trop. Med.
Hyg. 76, 470–474
25. Wu, Y., Przysiecki, C., Flanagan, E., Bello-Irizarry, S. N., Ionescu, R., Mu-
ratova, O., Dobrescu, G., Lambert, L., Keister, D., Rippeon, Y., Long, C. A.,
Shi, L., Caulfield, M., Shaw, A., Saul, A., Shiver, J., and Miller, L. H. (2006)
Proc. Natl. Acad. Sci. U. S. A. 103, 18243–18248
26. Kubler-Kielb, J., Majadly, F., Wu, Y., Narum, D. L., Guo, C., Miller, L. H.,
Shiloach, J., Robbins, J. B., and Schneerson, R. (2007) Proc. Natl. Acad. Sci.
U. S. A. 104, 293–298
27. Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Des-
mons, P., Wellde, B. T., Garcon, N., Krzych, U., andMarchand, M. (1997)
N. Engl. J. Med. 336, 86–91
Pfs48/45 Domain Organization and Subunit Vaccine Design
17156 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 23 • JUNE 8, 2007
